Document is current
Any future updates will be listed below
-
Authors
Franzén, Emilia M.C.
Eriksson, Marika I.
Satuli-Autere, Susanna
Ylinen, Anni
Jansson Sigfrids, Fanny
Nicklén, Jenna
Öhman, Hanna
Groop, Per-Henrik
Thorn, Lena M. https://orcid.org/0000-0003-3999-0390
,
-
Funding
Funding for this research was provided by:
University of Helsinki
- License Information
-
More Information
Article History
Received: 30 August 2025
Accepted: 27 October 2025
First Online: 18 November 2025
Declarations
:
: M.I.E. is a shareholder in BCB Medical Oy. F.J.S. has received lecture fees from AstraZeneca and Boehringer Ingelheim. P.-H.G. has received investigator-initiated research grants from Eli Lilly and Roche, is an advisory board member for AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Cebix, Eli Lilly, Janssen, Medscape, Merck Sharp & Dohme, Mundipharma, Nestlé, Novartis, Novo Nordisk, and Sanofi; and has received lecture fees from AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Merck Sharp & Dohme, Medscape, Menarini, Mundipharma, Novartis, Novo Nordisk, PeerVoice, Sanofi, and Sciarc.
: This study involves human participants and was approved by the Ethics Committee of Helsinki University Hospital (ID: 491/E5/2006, 238/13/03/00/2015, HUS/3313/2018). The study was performed in accordance with the Declaration of Helsinki. Participants gave informed consent to participate in the study before taking part.
